Shares of LogicBio Therapeutics Inc (NASDAQ:LOGC) have earned an average recommendation of “Buy” from the six analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $25.33.
A number of equities research analysts have recently issued reports on LOGC shares. Roth Capital started coverage on shares of LogicBio Therapeutics in a research note on Wednesday, May 1st. They issued a “buy” rating and a $26.00 price target on the stock. ValuEngine raised shares of LogicBio Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Zacks Investment Research raised shares of LogicBio Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Chardan Capital reissued a “buy” rating on shares of LogicBio Therapeutics in a research note on Monday, July 29th.
Several institutional investors have recently added to or reduced their stakes in the company. Deutsche Bank AG purchased a new stake in LogicBio Therapeutics during the 4th quarter worth approximately $115,000. Stanley Laman Group Ltd. purchased a new stake in LogicBio Therapeutics during the 2nd quarter worth approximately $254,000. Charles Schwab Investment Management Inc. increased its stake in LogicBio Therapeutics by 9.6% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 22,484 shares of the company’s stock worth $293,000 after buying an additional 1,969 shares during the period. Geode Capital Management LLC purchased a new stake in LogicBio Therapeutics during the 4th quarter worth approximately $626,000. Finally, Northern Trust Corp purchased a new stake in LogicBio Therapeutics during the 4th quarter worth approximately $873,000. 56.03% of the stock is currently owned by institutional investors and hedge funds.
LogicBio Therapeutics (NASDAQ:LOGC) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.04). Analysts expect that LogicBio Therapeutics will post -1.59 earnings per share for the current fiscal year.
LogicBio Therapeutics Company Profile
LogicBio Therapeutics, Inc, a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect.
Recommended Story: Hedge Funds – How They Work For Investors
Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.